Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
17.66
-1.23 (-6.51%)
At close: Jan 30, 2026, 4:00 PM EST
18.01
+0.35 (1.98%)
After-hours: Jan 30, 2026, 7:10 PM EST
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
273.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Coherus Oncology | 158 |
| Rezolute | 75 |
| Larimar Therapeutics | 65 |
| Atea Pharmaceuticals | 56 |
| Candel Therapeutics | 38 |
| Avalo Therapeutics | 23 |
| Immix Biopharma | 21 |
NGNE News
- 19 days ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 26 days ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 2 months ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 2 months ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Business Wire
- 3 months ago - Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Business Wire